The PBM Fight Is Happening in Courtrooms. Your Battle Is Happening at Renewal.

The lawsuits landing in federal courts this month aren't really about legal procedure. They're about money — specifically, who gets to keep the billions that move through the pharmaceutical supply chain before a drug ever reaches your employee.

If you run benefits for a company with fewer than 500 employees, you probably don't spend much time thinking about PBMs. You should.

Here's why this moment matters to your balance sheet.

What a PBM Actually Does (and Why It's Complicated)

PBM stands for Pharmacy Benefit Manager. They're the middlemen who sit between your health insurance carrier and the pharmacy where your employees fill prescriptions. On paper, they negotiate drug prices and process claims. In practice, they also collect rebates from drug manufacturers, set reimbursement rates for pharmacies, and determine which drugs show up on your formulary — the list of covered medications.

The margin opportunity in all of that is enormous. And for years, most of it has been invisible to plan sponsors — meaning you, the employer paying the bill.

State legislatures have started pushing back. Several states have passed or proposed laws requiring PBMs to be more transparent about what they're earning and how they're earning it. The pharmaceutical industry's response, this month, has been to sue to block those laws.

That tells you something important: the current system is worth fighting to protect.

Why Small and Midsize Employers Are Most Exposed

Large self-funded employers — think Fortune 500 companies with thousands of employees — often have actuaries, consultants, and legal teams auditing their pharmacy contracts. They can demand transparency because they have leverage.

A 60-person professional services firm or a 200-person manufacturer? They're typically bundled into a fully-insured or level-funded plan (level-funded means you pay a fixed monthly amount, but the carrier invests the surplus and keeps the claims data) where the PBM arrangement is buried inside the carrier contract. You pay the premium. You rarely see the pharmacy economics underneath it.

The less you can see, the less you can manage. That's not a platitude — it's a structural disadvantage.

The Three PBM Levers Most Employers Never Touch

You may not control what happens in federal court, but you have more leverage than you think on your own plan. Here's a framework to apply this quarter.

1. Ask for a pharmacy carve-out analysis.

Most bundled plans include pharmacy through the carrier's preferred PBM. A carve-out means separating your pharmacy benefit from your medical benefit and managing it independently — often with a PBM that works on a transparent, pass-through model. In a pass-through arrangement, the PBM charges a flat administrative fee and passes the drug manufacturer rebates directly back to the plan. Ask your broker or consultant whether your current plan even allows you to see the rebate figures. If they can't answer, that's the answer.

2. Understand your formulary's incentive structure.

Formularies are not built purely on clinical evidence. Drug manufacturers pay to have their products placed favorably — those payments are called rebates. A rebate-maximized formulary might push employees toward a brand-name drug that generates a large rebate for the PBM, even when a generic or biosimilar (a near-identical version of a biologic drug) would cost your plan significantly less. Ask your carrier or PBM point-blank: is this formulary optimized for net plan cost, or for rebate generation?

3. Pull your specialty drug spend separately.

Specialty drugs — typically biologics used to treat conditions like rheumatoid arthritis, Crohn's disease, or certain cancers — often represent a small percentage of your claims count but a large percentage of your total drug spend. In many midsize employer plans, specialty drugs drive the majority of pharmacy cost. Knowing your specialty exposure before renewal gives you options: point-of-sale rebate programs, manufacturer copay assistance for eligible members, or alternative funding arrangements. You can't negotiate what you haven't measured.

What the Lawsuits Signal for Employers

The legal fight over state PBM transparency laws will take time to resolve. Some laws may survive. Others won't. Waiting for regulators to fix this for you is a losing strategy.

The better read: the fact that these laws exist, and that they're being aggressively contested, confirms that meaningful money is moving through this system in ways that haven't been visible to the people paying the bills. Employers who figure out how to see it — through transparent contract structures, independent audits, or better-informed broker relationships — will have a structural cost advantage over those who don't.

Benefits belong on the balance sheet. Pharmacy spend is increasingly the line item that determines whether your renewal goes up 8% or 22%.

What to Do Before Your Next Renewal

You don't need to overhaul your plan this week. You need to ask three questions of whoever manages your benefits:

• Can I see the rebate dollars flowing through my pharmacy benefit?
• Is my formulary designed to minimize net plan cost, or to maximize PBM revenue?
• What is my specialty drug exposure, and what tools do I have to manage it?

If the answers are vague, incomplete, or "that's just how it works," you're leaving leverage on the table.

If you want a deeper framework for evaluating your pharmacy benefit before your next renewal, Think Insurance Group has a strategy session available for plan sponsors who want to work through it. You can book a 30-minute call at thinkinsurancegroup.com.

The courtroom fight is out of your hands. The contract you sign next renewal isn't.

---

This article is published by The Benefits CEO, the media brand of Think Insurance Group, and is intended for general educational purposes only. It does not constitute legal, tax, medical, or insurance advice. Consult qualified professionals regarding your specific plan and circumstances.